Dr. Dali Ding, Partner of YiMei Capital, passed away on the night of January 3, 2023.
Dr. Dali Ding, Partner of YiMei Capital, passed away in Jakarta on the night of January 3, 2023, after a sudden fall.
We grieve the loss of a beloved colleague. We will share information about the memorial event once details are finalized.
Thank you for your concern, understanding and support.
Judy Qing Ye
January 8, 2023
YiMei Capital & Peking University Education Foundation Joint Investment Intern Recruitment
YiMei Capital, a top-notch FoF equity manager and Peking University Education Foundation has been committed to provide top-talent students with first-hand investment intern opportunities. This full circle of intern recruitment, employment and training is joint by the two parties, providing interns with practical experiences no less than six-month in the fields of endowment fund’s asset allocation, various asset investment and equity investment.
In this joint internship, students will have a deep understanding of institutional investors, know-how of the practical asset allocation strategy and management. We believe this opportunity will enhance student’s experience in the relative fields and be able to find the best talents to further pursue in the development of endowment fund and Peking University’s Education in the long-run.
This internship locates in Beijing, and for any further information or enquiries, please visit http://www.pkuef.org/info/1173/6388.htm.
October 22, 2019
,
Beijing, CHINA
YiMei Awarded Top 20 China Best FoFs, China Best LPs in Venture Capital and China GP's most focused FoFs by ChinaVenture
ChinaVenture, one of the most influential venture capital media held its 13th Inestment Conference LP/GP Summit in Beijing. And during the summit, YiMei Capital has been awarded with three titles, incluing Top 20 China Best FoFs, Top 20 China Best LPs in Venture Capital, and China GP's most focused Top 20 FoFs. During the summit, Mr. Mark He, partner of YiMei Capital was invited to speak on the current development of RMB Fund and its future development.
October 15, 2019
,
Shanghai, CHINA
KEBODA LISTED ON SSE MAIN BOARD
KEBODA Technology Co., Ltd. (603786) was officially listed and traded on the main board of SSE. Founded in September 2003, the company has focused on the development trends of intelligence and green power technology for the automotive industry, as well as the technological innovation and industrialization of automotive electronics, automotive electric appliance, engine components and automotive wire harness.
KEBODA has successfully integrated itself into the high-end global automotive electronics industry supply chain, with a portfolio of advanced and world-leading products. At the same time, it provides product supports and technical services for domestic mainstream OEMs.
Its end users include dozens of world-renowned vehicle manufacturers, such as Volkswagen Group (including its subsidiaries Audi, Porsche, Bentley and Lamborghini), Daimler, Jaguar Land Rover, FAW Group and SAIC Volkswagen, and some new products have entered the supplier system of Ford, BMW and Renault.
YiMei Capital invested in Shanghai Fosun Weishi Fund I, which invested in KEBODA in June 2016. Fosun Weishi Fund I exited from KEBODA through its IPO, with a book return of 2.8 times.
September 19, 2019
,
Shanghai, CHINA
YiMei Managing Partner, Ms. Judy Q. Ye shared YiMei views on 2019 Shanghai Jing'An International Big-Data Forum
Ms. Judy Ye was invited to the 2019 Shanghai Jing'An International Big-Data Form, and shared her insights on the subject matter as below:
The development of digital industry will realign China's traditional industrial chain, transform yesterday’s low value-add manufacturing and export strategy, and improve the overall competitiveness of China.
Big Data, AI and other leading high-tech industries have been the longterm focus of YiMei. Investment thesis has been developed to capture opportunities in technology application across various verticals, from MedTech, ConsumerTech, Fintech, EdTech, to other verticals such as Real Estate and driverless transportation. Other macro factors, including the short-term liquidity shortage caused by China’s deleveraging process, with the backdrop of rising domestic consumer demand and improving public equity market, have offered global investors a unique long-term investment opportunity at a very attractive pricing point in the near future.
August 12, 2019
,
Shanghai, China
CHIPSCREEN BIOSCIENCES Listed in SSE STAR Market Today
CHIPSCREEN BIOSCIENCES listed in SSE STAR Market Today, with 467 p/e ratio and market value exceeding 40 Billion RMB. In 2001, CHIPSCREEN BIOSCIENCES was founded in Shenzhen, specializing in the research and development of original small molecule drugs. With the self-created "integrated drug discovery and early evaluation platform based on chemical genetics" as its core competitiveness, CHIPSCREEN BIOSCIENCES has now become one of China's leading innovative drug enterprises, forming a modern biomedicine group company in Shenzhen. Moreover, the company has actively participated in shaping national pharmaceutical industry policies and undertaken a number of major national science and technology projects.
CHIPSCREEN BIOSCIENCES is one of YiMei's investment portfolios.